A CRO cannot outperform the sponsor operating model it's beholden to.  That may be uncomfortable to say, but it is often true.

A CRO can have strong therapeutic expertise, an experienced study team, and sound processes and still struggle to deliver when biotech and emerging biopharma priorities shift without clarity, decisions stall, or internal capacity is invisible until it becomes a bottleneck.

CRO governance is typically…